TGFB1 and pulmonary fibrosis: The results of this study found that when BFC-TA treats pulmonary fibrosis through the TGF-β-related signaling pathway, the therapeutic effect of the BFC-TA high-dose group (136.mg/kg) is close to the therapeutic effect of the PFD positive control (150 mg/kg), even better than the PFD group.